Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in mice - PubMed (original) (raw)

. 2010 Dec;31(12):1547-52.

doi: 10.1038/aps.2010.164. Epub 2010 Nov 22.

Yu-hua WANG, Fu-ying LI, Gang LU, Yi-min TAO, Yun CHENG, Jie CHEN, Xue-jun XU, Zhi-qiang CHI, John L NEUMEYER, Ao ZHANG, Jing-gen LIU

Affiliations

Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in mice

Jian-feng SUN et al. Acta Pharmacol Sin. 2010 Dec.

Abstract

Aim: to investigate the effects of ATPM-ET [(-)-3-N-Ethylaminothiazolo [5,4-b]-N-cyclopropylmethylmorphinan hydrochloride] on physical dependence and behavioral sensitization to morphine in mice.

Methods: the pharmacological profile of ATPM-ET was characterized using competitive binding and GTPγS binding assays. We then examined the antinociceptive effects of ATPM-ET in the hot plate test. Morphine dependence assay and behavioral sensitization assay were used to determine the effect of ATPM-ET on physical dependence and behavior sensitization to morphine in mice.

Results: the binding assay indicated that ATPM-ET ATPM-ET exhibited a high affinity to both κ- and μ-opioid receptors with K(i) values of 0.15 nmol/L and 4.7 nmol/L, respectively, indicating it was a full κ-opioid receptor agonist and a partial μ-opioid receptor agonist. In the hot plate test, ATPM-ET produced a dose-dependent antinociceptive effect, with an ED(50) value of 2.68 (2.34-3.07) mg/kg. Administration of ATPM-ET (1 and 2 mg/kg, sc) prior to naloxone (3.0 mg/kg, sc) injection significantly inhibited withdrawal jumping of mice. In addition, ATPM-ET (1 and 2 mg/kg, sc) also showed a trend toward decreasing morphine withdrawal-induced weight loss. ATPM-ET (1.5 and 3 mg/kg, sc) 15 min before the morphine challenge significantly inhibited the morphine-induced behavior sensitization (P<0.05).

Conclusion: ATPM-ET may have potential as a therapeutic agent for the treatment of drug abuse.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Chemical structure of ATPM-ET.

Figure 2

Figure 2

Effects of ATPM-ET and (−)U50,488H on naloxone-precipitated jumping and body weight loss in mice treated chronically with morphine. Mice were treated with progressively increasing doses of either ATPM-ET or morphine alone or treated with progressively increasing doses of morphine concomitantly with ATPM-ET (0.1–2 mg/kg, subcutaneously) or (-)U50,488H (2 mg/kg, subcutaneously) for 5 days. Morphine withdrawal jumping and body weight loss were precipitated by naloxone (3 mg/kg, subcutaneously). (A) The number of jumping events was measured for 30 min after naloxone injection. (B) Body weight loss was measured initially and 30 and 60 min after the naloxone injection. Data were presented as the mean±SEM from 10 animals. b_P_<0.05, c_P_<0.01 vs morphine alone.

Figure 3

Figure 3

The induction of morphine sensitization in mice. Two groups were given morphine (10 mg/kg, subcutaneously) or saline (10 mL/kg, subcutaneously) for 7 consecutive days and their activity was measured for 1 h after each administration of drug (or saline) on days 1, 4, and 7. Data are shown as means±SEM. (n_=10 per group). b_P<0.05, c_P_<0.01 vs the corresponding saline group. e_P_<0.05, f_P_<0.01 vs the first administration group.

Figure 4

Figure 4

Effect of ATPM-ET on morphine-induced behavioral sensitization. Mice in the control group were given saline, and the other mice received morphine (10 mg/kg, subcutaneously) for 7 consecutive days. After a 7-d washout period, the mice were challenged with morphine (10 mg/kg, subcutaneously) 15 min after an injection of ATPM-ET (0.75, 1.5, 3 mg/kg, subcutaneously). The mice were then put into test chambers to measure their locomotor activity for 1 h. Data are presented as means±SEM (n_=10 per group). c_P<0.01 vs saline group. e_P_<0.05 vs morphine sensitized/saline group.

Similar articles

Cited by

References

    1. Wells JL, Bartlett JL, Ananthan S, Bilsky EJ. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J Pharmacol Exp Ther. 2001;297:597–605. - PubMed
    1. Sepulveda J, Ortega A, Zapata G, Contreras E. Acamprosate decreases the induction of tolerance and physical dependence in morphine-treated mice. Eur J Pharmacol. 2002;445:87–91. - PubMed
    1. Fattore L, Spano MS, Deiana S, Melis V, Cossu G, Fadda P, et al. An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev. 2007;53:1–16. - PubMed
    1. Lyvers M. Drug addiction as a physical disease: the role of physical dependence and other chronic drug-induced neurophysiological changes in compulsive drug self-administration. Exp Clin Psychopharmacol. 1998;6:107–25. - PubMed
    1. Bell K, Salmon A. Pain, physical dependence and pseudoaddiction: redefining addiction for 'nice' people. Int J Drug Policy. 2009;20:170–8. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources